STOCK TITAN

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.

Soligenix Inc (SNGX) is a biopharmaceutical innovator developing therapies for rare diseases and biodefense solutions. This page provides official updates on clinical trials, regulatory milestones, and scientific advancements across its two core segments: specialized therapeutics for conditions like cutaneous T-cell lymphoma (CTCL) and public health vaccines for biological threats.

Investors and researchers will find timely announcements about HyBryte™ photodynamic therapy progress, ThermoVax® platform developments, and partnership updates. Content spans trial results, FDA designations, manufacturing collaborations, and research publications – all essential for understanding SNGX's position in niche therapeutic markets.

Bookmark this page for structured access to Soligenix's verified news, organized to help stakeholders monitor advancements in orphan drug candidates and heat-stable vaccine technologies. Regular updates ensure you stay informed about this innovator's progress in addressing high-need, low-competition medical challenges.

Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced that dusquetide shows significant efficacy in reducing tumor size in nonclinical models, reinforcing previous studies. It was effective both as a standalone therapy and in combination with radiation and chemotherapy for the MCF-7 breast cancer cell line. Dusquetide has also shown positive results in reducing severe oral mucositis, leading to enhanced survival rates. The company is exploring further product opportunities in oncology, motivated by strong Phase 2 and 3 study data. Dusquetide holds Fast Track Designation for treating oral mucositis, with a robust intellectual property portfolio backing its development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) announced successful 100% protection of non-human primates against lethal Sudan ebolavirus using a bivalent, thermostabilized vaccine. This achievement highlights the potential of their vaccine platform, crucial for pandemic preparedness. The vaccine maintains full potency and can be reconstituted with just water, enabling storage at ambient temperatures. The ongoing collaboration with the University of Hawaiʻi aims to accelerate vaccine development for various filoviruses, including Sudan and Marburg, which currently lack effective vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.88%
Tags
none
-
Rhea-AI Summary

Soligenix (SNGX) announced its Q3 2021 financial results, reporting revenues of $0.2 million compared to $0.6 million in Q3 2020. The net loss increased to $3.6 million or ($0.09) per share, driven by reduced revenues and higher R&D costs primarily for HyBryte™. The Company holds approximately $29 million in cash and is preparing for an NDA filing for HyBryte™, which has received orphan drug designation for T-cell lymphoma. Additionally, Soligenix plans to expand synthetic hypericin development into psoriasis with a Phase 2a trial set for mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced it received a Pediatric Investigation Plan (PIP) waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for its treatment, HyBryte™ (SGX301), for cutaneous T-cell lymphoma (CTCL). This waiver facilitates regulatory processes in the UK, avoiding costly pediatric clinical studies. Earlier, the EMA granted a similar waiver. The Phase 3 FLASH trial demonstrated significant efficacy, with 40% of patients responding positively to HyBryte™. Soligenix emphasizes the safety of HyBryte™ compared to existing therapies, marking a crucial step in advancing its clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced a new publication confirming that its RiVax® vaccine offers enduring protection against ricin toxin for at least 12 months post-vaccination. The findings were published in mSphere and highlight previous efficacy trials in animals. The vaccine's thermostability could facilitate stockpiling for emergency use. Soligenix intends to pursue FDA approval under the 'Animal Rule,' given the ethical concerns of human trials. The development is backed by over $40 million in non-dilutive funding. RiVax® has received Orphan Drug and Fast Track designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced that Dr. Oreola Donini, the Chief Scientific Officer, will present key data on the company's thermostable vaccine technology at the 6th International Conference on Vaccines Research and Development from November 1-3, 2021. The presentation will highlight the ricin toxin vaccine RiVax®, and COVID-19 vaccine CiVax™. Notably, RiVax® has shown up to 100% protection against ricin in non-human primates, remaining potent for over 12 months at elevated temperatures. The company's vaccine platforms aim to reduce logistical challenges in pandemic response.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced its poster abstract on HyBryte™ was chosen as a top abstract for presentation at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit on October 18-19, 2021. The FLASH trial, which is the largest study for treating cutaneous T-cell lymphoma (CTCL), showed positive Phase 3 results. Key findings include a 16% lesion reduction in the HyBryte™ group versus 4% in the placebo, demonstrating a favorable safety profile. The company continues to advance the regulatory approval process for this innovative photodynamic therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.67%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) has published promising pre-clinical results for its heat-stable COVID-19 vaccine candidate, CiVax™, demonstrating broad-spectrum neutralizing antibodies against various variants including Beta, Gamma, and Delta. Funded by a $1.5M SBIR grant from NIAID, the study shows that CiVax™ elicited durable immune responses in non-human primates and improved protection against viral loads. The vaccine's ambient temperature stability could enhance global vaccination efforts, reducing logistical challenges. CEO Christopher Schaber highlighted potential impacts on pandemic resolution and future vaccine preparedness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
covid-19
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced that CEO Christopher J. Schaber, PhD, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021, at 8:00 AM ET. The event will allow for virtual one-on-one meetings with registered attendees. The company is focused on treating rare diseases with unmet medical needs, including the development of HyBryte™ for cutaneous T-cell lymphoma and vaccine candidates for infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences
Rhea-AI Summary

Soligenix, Inc. (SNGX) announced the positive outcome of its pivotal Phase 3 FLASH study, validating the efficacy of synthetic hypericin for cutaneous T-cell lymphoma (CTCL). Following this, the company aims to expand the use of synthetic hypericin, also known as SGX302, into the treatment of psoriasis, a chronic skin condition affecting millions. The treatment utilizes visible light activation, minimizing long-term risks associated with traditional therapies. With promising results from earlier studies, Soligenix plans to initiate a Phase 2a trial for psoriasis in late 2022, without needing to raise additional capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

SNGX Stock Data

6.63M
3.15M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON